Debate: Lipid-lowering Therapies and Diabetes Development

Overview

Journal Curr Atheroscler Rep

Publisher Springer

Specialty Cardiology & Vascular Diseases

Date 2025 Jan 8

PMID 39775321

Authors

Julia Brandts

Dirk Muller-Wieland

Affiliations

Soon will be listed here.

Abstract

Purpose Of Review: This review explores the relationship between lipid-lowering therapies, particularly statins, and the risk of new-onset diabetes (NOD). It examines the underlying mechanisms and evaluates whether other lipid-lowering agents present similar risks.

Recent Findings: Recent meta-analyses further underscore a dose-dependent increase in NOD risk with statin therapy, particularly with high-intensity statins. In contrast to other LDL-cholesterol lowering drugs and their impact on lipid metabolism in the liver, genetic and experimental studies indicate that statins may impair insulin secretion through various mechanisms, including alterations in small G protein function, calcium signaling, and cholesterol homeostasis in pancreatic beta cells. This might contribute to the increased risk of NOD. Statins effectively reduce cardiovascular events but increase the risk of NOD, potentially via intracellular pathways affecting liver and beta-cell function. Despite the cardiovascular benefits of statins, personalized treatment strategies and alternative lipid-lowering therapies may offer safer options for patients at risk of diabetes, potentially shaping future clinical guidelines and therapeutic approaches.

References

Lorza-Gil E, Salerno A, Wanschel A, Vettorazzi J, Ferreira M, Rentz T . Chronic use of pravastatin reduces insulin exocytosis and increases β-cell death in hypercholesterolemic mice. Toxicology. 2016; 344-346:42-52. DOI: 10.1016/j.tox.2015.12.007. View

Nissen S, Lincoff A, Brennan D, Ray K, Mason D, Kastelein J . Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients. N Engl J Med. 2023; 388(15):1353-1364. DOI: 10.1056/NEJMoa2215024. View

Sabatine M, Leiter L, Wiviott S, Giugliano R, Deedwania P, De Ferrari G . Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol. 2017; 5(12):941-950. DOI: 10.1016/S2213-8587(17)30313-3. View

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

Ray K, Nicholls S, Li N, Louie M, Brennan D, Lincoff A . Efficacy and safety of bempedoic acid among patients with and without diabetes: prespecified analysis of the CLEAR Outcomes randomised trial. Lancet Diabetes Endocrinol. 2023; 12(1):19-28. DOI: 10.1016/S2213-8587(23)00316-9. View

Sattar N, Preiss D, Murray H, Welsh P, Buckley B, de Craen A . Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010; 375(9716):735-42. DOI: 10.1016/S0140-6736(09)61965-6. View

Sabatine M, Giugliano R, Keech A, Honarpour N, Wiviott S, Murphy S . Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. N Engl J Med. 2017; 376(18):1713-1722. DOI: 10.1056/NEJMoa1615664. View

Horton J, Goldstein J, Brown M . SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002; 109(9):1125-31. PMC: 150968. DOI: 10.1172/JCI15593. View

Yada T, Nakata M, Shiraishi T, Kakei M . Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol. 1999; 126(5):1205-13. PMC: 1565875. DOI: 10.1038/sj.bjp.0702397. View

10.

. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis. Lancet Diabetes Endocrinol. 2024; 12(5):306-319. PMC: 7615958. DOI: 10.1016/S2213-8587(24)00040-8. View

11.

Preiss D, Seshasai S, Welsh P, Murphy S, Ho J, Waters D . Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011; 305(24):2556-64. DOI: 10.1001/jama.2011.860. View

12.

Shen L, Gu Y, Qiu Y, Cheng T, Nie A, Cui C . Atorvastatin Targets the Islet Mevalonate Pathway to Dysregulate mTOR Signaling and Reduce β-Cell Functional Mass. Diabetes. 2019; 69(1):48-59. DOI: 10.2337/db19-0178. View

13.

Freeman D, Norrie J, Sattar N, Neely R, Cobbe S, Ford I . Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001; 103(3):357-62. DOI: 10.1161/01.cir.103.3.357. View

14.

Xia F, Gao X, Kwan E, Lam P, Chan L, Sy K . Disruption of pancreatic beta-cell lipid rafts modifies Kv2.1 channel gating and insulin exocytosis. J Biol Chem. 2004; 279(23):24685-91. DOI: 10.1074/jbc.M314314200. View

15.

Shah N, McGuire D, Cannon C, Giugliano R, Lokhnygina Y, Page C . Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT. J Am Heart Assoc. 2023; 12(13):e029593. PMC: 10356081. DOI: 10.1161/JAHA.122.029593. View

16.

Xia F, Xie L, Mihic A, Gao X, Chen Y, Gaisano H . Inhibition of cholesterol biosynthesis impairs insulin secretion and voltage-gated calcium channel function in pancreatic beta-cells. Endocrinology. 2008; 149(10):5136-45. DOI: 10.1210/en.2008-0161. View

17.

Culver A, Ockene I, Balasubramanian R, Olendzki B, Sepavich D, Wactawski-Wende J . Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012; 172(2):144-52. DOI: 10.1001/archinternmed.2011.625. View

18.

Perego C, Da Dalt L, Pirillo A, Galli A, Catapano A, Norata G . Cholesterol metabolism, pancreatic β-cell function and diabetes. Biochim Biophys Acta Mol Basis Dis. 2019; 1865(9):2149-2156. DOI: 10.1016/j.bbadis.2019.04.012. View

19.

Baigent C, Keech A, Kearney P, Blackwell L, Buck G, Pollicino C . Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005; 366(9493):1267-78. DOI: 10.1016/S0140-6736(05)67394-1. View

20.

Wang X, Huang R, Zhang L, Li S, Luo J, Gu Y . A severe atherosclerosis mouse model on the resistant NOD background. Dis Model Mech. 2018; 11(10). PMC: 6215432. DOI: 10.1242/dmm.033852. View